| abstract |
New pyrimidinedione compounds and their pharmaceutically acceptable salts suitable for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction are envisioned. The synthesis and characterization of compounds and their pharmaceutically acceptable salts, as well as methods for treating NSM and other forms of heart disease, are described. |